TY - JOUR
T1 - Growth hormone treatment in children in Israel
T2 - A large-scale retrospective database study
AU - Reichenberg, Yael
AU - Bello, Rachel
AU - Oberman, Bernice
AU - Cohen, Moryia
AU - Cohen, Avner Herman
AU - Shkalim Zemer, Vered
N1 - Publisher Copyright:
© 2024 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
PY - 2024
Y1 - 2024
N2 - Aim: To evaluate the indications, population characteristics and latency between short stature diagnosis to treatment with recombinant growth hormone (GH) therapy in a large cohort of children in Israel. Methods: We performed a retrospective medical chart review of all children treated with GH for conditions associated with short stature in three central districts in Israel from 1 January 2010 to 31 December 2021. Data extracted from the medical files included demographics, time to diagnosis, treatment indications and GH therapy duration. Results: The study group comprised 5148 children aged 1 day to 17 years. A total of 64.1% were diagnosed with idiopathic short stature (ISS), 31.1% with GH deficiency (GHD) and 2.5% with small-for-gestational age (SGA). Males were treated more than females (58.9% vs. 41.1%). The mean age at first documentation of short stature was 6.9 ± 3.5 years. GH therapy was initiated at a mean age of 9.8 ± 3.3 years. A total of 51.2% were of high socio-economic status (SES); 78.2% were non-ultraorthodox Jews, 13%, ultraorthodox Jews, and 8.8% were Arabs. Conclusion: Meticulous growth follow-up from early childhood for all children, specifically females, those of low SES, and minorities is important to provide appropriate referral, treatment and final adult height outcomes.
AB - Aim: To evaluate the indications, population characteristics and latency between short stature diagnosis to treatment with recombinant growth hormone (GH) therapy in a large cohort of children in Israel. Methods: We performed a retrospective medical chart review of all children treated with GH for conditions associated with short stature in three central districts in Israel from 1 January 2010 to 31 December 2021. Data extracted from the medical files included demographics, time to diagnosis, treatment indications and GH therapy duration. Results: The study group comprised 5148 children aged 1 day to 17 years. A total of 64.1% were diagnosed with idiopathic short stature (ISS), 31.1% with GH deficiency (GHD) and 2.5% with small-for-gestational age (SGA). Males were treated more than females (58.9% vs. 41.1%). The mean age at first documentation of short stature was 6.9 ± 3.5 years. GH therapy was initiated at a mean age of 9.8 ± 3.3 years. A total of 51.2% were of high socio-economic status (SES); 78.2% were non-ultraorthodox Jews, 13%, ultraorthodox Jews, and 8.8% were Arabs. Conclusion: Meticulous growth follow-up from early childhood for all children, specifically females, those of low SES, and minorities is important to provide appropriate referral, treatment and final adult height outcomes.
KW - children
KW - growth hormone deficiency
KW - growth hormone treatment
KW - idiopathic short stature
KW - small-for-gestational age
UR - http://www.scopus.com/inward/record.url?scp=85211149210&partnerID=8YFLogxK
U2 - 10.1111/apa.17535
DO - 10.1111/apa.17535
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39641586
AN - SCOPUS:85211149210
SN - 0803-5253
JO - Acta Paediatrica, International Journal of Paediatrics
JF - Acta Paediatrica, International Journal of Paediatrics
ER -